Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment

Gilles Capellier, Hélène Mockly, Claire Charpentier, Djillali Annane, Gilles Blasco, Thibault Desmettre, Antoine Roch, Christophe Faisy, Joel Cousson, Samuel Limat, Mariette Mercier, Laurent Papazian, Gilles Capellier, Hélène Mockly, Claire Charpentier, Djillali Annane, Gilles Blasco, Thibault Desmettre, Antoine Roch, Christophe Faisy, Joel Cousson, Samuel Limat, Mariette Mercier, Laurent Papazian

Abstract

Purpose: The optimal treatment duration for ventilator-associated pneumonia is based on one study dealing with late-onset of the condition. Shortening the length of antibiotic treatment remains a major prevention factor for the emergence of multiresistant bacteria.

Objective: To demonstrate that 2 different antibiotic treatment durations (8 versus 15 days) are equivalent in terms of clinical cure for early-onset ventilator-associated pneumonia.

Methods: Randomized, prospective, open, multicenter trial carried out from 1998 to 2002.

Measurements: The primary endpoint was the clinical cure rate at day 21. The mortality rate was evaluated on days 21 and 90.

Results: 225 patients were included in 13 centers. 191 (84.9%) patients were cured: 92 out of 109 (84.4%) in the 15 day cohort and 99 out of 116 (85.3%) in the 8 day cohort (difference = 0.9%, odds ratio = 0.929). 95% two-sided confidence intervals for difference and odds ratio were [-8.4% to 10.3%] and [0.448 to 1.928] respectively. Taking into account the limits of equivalence (10% for difference and 2.25 for odds ratio), the objective of demonstrative equivalence between the 2 treatment durations was fulfilled. Although the rate of secondary infection was greater in the 8 day than the 15 day cohort, the number of days of antibiotic treatment remained lower in the 8 day cohort. There was no difference in mortality rate between the 2 groups on days 21 and 90.

Conclusion: Our results suggest that an 8-day course of antibiotic therapy is safe for early-onset ventilator-associated pneumonia in intubated patients.

Trial registration: ClinicalTrials.gov NCT01559753.

Conflict of interest statement

Competing Interests: The authors have read the journal's policy and have the following conflicts: Glaxo and Beecham Laboratory were part funders of this study. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1. Design of the study governing…
Figure 1. Design of the study governing inclusion of a new patient according to BAL bacteriological results and follow up criteria.
Figure 2. Data regarding number of patients…
Figure 2. Data regarding number of patients included, treated according to protocol and followed up at 21 and 90 days.

References

    1. Fagon JY, Stephan F, Novara A (1995) Epidemiologie des pneumopathies acquises sous ventilation artificielle. In: Chastre J, Fagon JY, editors. Pneumopathies nosocomiales et ventilation artificielle. Paris: Masson. pp. 1–12.
    1. Joshi N, Localio AR, Hamory BH (1992) A predictive risk index for nosocomial pneumonia in the intensive care unit. Am J Med 93: 135–142.
    1. Bregeon F, Papazian L, Visconti A, Gregoire R, Thirion X, et al. (1997) Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilator-associated pneumonia. JAMA 277: 655–662.
    1. Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165: 867–903.
    1. A'Court CD, Garrard CS (1995) Nosocomial pneumonia in the ICU: New perspectives on current controversies. In Vincent JL, editor. Yearbook of Intensive Care and Emergency Medicine. Berlin: Springer-Verlag. pp. 726–747.
    1. Craven DE, Steger KA, Barat LM, Duncan RA (1992) Nosocomial pneumonia: Epidemiology and infection control. Intensive Care Med 18: S3–9.
    1. Giard M, Lepape A, Allaouchiche B, Guerin C, Lehot JJ, et al. (2008) Early- and late-onset ventilator-associated pneumonia acquired in the intensive care unit: comparison of risk factors. J Crit Care 23: 27–33.
    1. Verhamme KM, De Coster W, De Roo L, De Beenhouwer H, Nollet G, et al. (2007) Pathogens in early-onset and late-onset intensive care unit-acquired pneumonia. Infect Control Hosp Epidemiol 28: 389–97.
    1. Gastmeier P, Sohr D, Geffers C, Rüden H, Vonberg RP, et al. (2009) Early- and late-onset pneumonia: is this still a useful classification? Antimicrob Agents Chemother 53: 2714–8.
    1. Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, et al. (2010) Nosocomial Pneumonia in the Intensive Care Unit Acquired during Mechanical Ventilation or Not. Am J Respir Crit Care Med 182: 1533–1539.
    1. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, et al. (2003) Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 290: 2588–2598.
    1. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL (2000) Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162: 505–511.
    1. Luyt CE, Chastre J, Fagon JY (2004) Value of the clinical pulmonary infection score for the identification and management of ventilator-associated pneumonia. Intensive Care Med 30: 844–852.
    1. Charles PE, Kus E, Aho S, Prin S, Doise JM, et al. (2009) Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: A preliminary report. BMC Infect Dis 9: 49.
    1. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, et al. (2010) Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375: 463–74.
    1. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ (2001) Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 163: 1371–1375.
    1. Marrie TJ (1994) Community-acquired pneumonia. Clin Infect Dis 18: 501–513 quiz 514-505.
    1. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia (2005) Am J Respir Crit Care Med 171: 388–416.
    1. Rotstein C, Evans G, Born A, Grossman R, Light RB, et al. (2008) Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol 19: 19–53.
    1. Masterton RG, Galloway A, French G, et al. (2008) Guidelines for themanagement of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 62: 5–34.
    1. Capellier G (2003) Nosocomial pneumonia. When to stop antibiotherapy (paper presented at the annual meeting of the International Symposium on Intensive Care and Emergency Medicine, Bruxelles).
    1. Capellier G (2004) Comparaison de deux durées de traitements au cours des pneumopathies nosocomiales précoces acquises sous ventilation mécanique: 8 jours versus 15 jours (paper presented at the annual meeting of the Société Française de Réanimation Médicale, Paris).
    1. Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E, et al. (2005) Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 31: 1488–94.
    1. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C (1999) Canadian Critical Care Trials Group (1999) The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Am J Respir Crit Care Med 159: 1249–56.
    1. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, et al. (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157: 531–39.
    1. Weinberg PF, Matthay MA, Webster RO, Roskos KV, Goldstein IM, et al. (1984) Biologically active products of complement and acute lung injury in patients with the sepsis syndrome. Am Rev Respir Dis 130: 791–796.
    1. SFAR (1992) Antibioprophylaxie en milieu chirurgical chez l'adulte. Paris: Réanimation SFAR editor.230 p.
    1. Dunnett CW, Gent M (1977) Significance testing to establish equivalence between treatments, with special reference to data in the form of 2×2 tables. Biometrics 33: 593–602.
    1. Gart JJ (1971) The comparison of proportions: A review of significance tests, confidence interval and adjustments for stratification. Review of the International Statistical Institute 39: 148–169.
    1. Koeman M, Bonten MJ (2003) When can empiric therapy for intensive care unit-acquired pneumonia be withheld or withdrawn? Semin Respir Infect 18: 122–8.
    1. Nachtigall I, Tamarkin A, Tafelski S, Deja M, Halle E, et al. (2009) Impact of adherence to standard operating procedures for pneumonia on outcome of intensive care unit patients. Crit Care Med 37: 159–166.
    1. Ferrer M, Liapikou A, Valencia M, Esperatti M, Theessen A, et al. (2010) Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit. Clin Infect Dis 50: 945–52.
    1. Leone M, Garcin F, Bouvenot J, Boyadjev I, Visintini P, et al. (2007) Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 35: 379–85.
    1. Lancaster JW, Lawrence KR, Fong JJ, Doron SI, Garpestad E, et al. (2008) Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomes. Pharmacotherapy 28: 852–862.
    1. Combes A, Figliolini C, Trouillet JL, Kassis N, Wolff M, et al. (2002) Incidence and outcome of polymicrobial ventilator-associated pneumonia. Chest 121: 1618–1623.
    1. Brun-Buisson C, Sollet JP, Schweich H, Briere S, Petit C (1998) Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis 26: 346–54.
    1. Alvarez-Lerma F, Insausti-ordenana J, Jorda-marcos R, Maravii-Poma E, Torres Marti A, et al. (2001) Efficacy and tolerability of piperacillin tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 27: 493–502.
    1. Fagon JY, Patrick H, Haas DW, Torres A, Gibert C, et al. (2000) Treatment of Gram-positive Nosocomial Pneumonia: Prospective Randomized Comparison of Quinupristin/Dalfopristin versus Vancomycin. Am J Respir Crit Care Med 161: 753–62.
    1. Pugh RJ, Cooke RP, Dempsey G (2010) Short course antibiotic therapy for Gram-negative hospital-acquired pneumonia in the critically ill. J Hosp Infect 74: 337–43.
    1. Luna CM, Blanzaco D, Niederman MS, Matarucco W, Baredes NC, et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 31: 676–682.
    1. Vidaur L, Planas K, Sierra R, Dimopoulos G, Ramirez A, et al. (2008) Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization. Chest 133: 625–32.
    1. Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, et al. (2007) Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia. Crit Care Med 35: 146–54.
    1. Cook DJ, Mulrow CD, Haynes RB (1997) Systematic reviews: Synthesis of best evidence for clinical decisions. Ann Intern Med 126: 376–380.
    1. Osmon S, Warren D, Seiler SM, Shannon W, Fraser VJ, et al. (2003) The Influence of Infection on Hospital Mortality for Patients Requiring >48 h of Intensive Care. Chest 124: 1021–1029.
    1. Meduri GU, Mauldin GL, Wunderink RG, Leeper KV, Jones CB, et al. (1994) Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest 106: 221–235.
    1. Heyland DK, Dodek P, Muscedere J, Day A, Cook D (2008) Canadian critical care trials group (2008) Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 36: 737–44.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する